Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study

Basit Öğe Kaydı
dc.authorid0000-0002-5734-3480
dc.contributor.authorAlbiges, L.
dc.contributor.authorRini, B. I.
dc.contributor.authorPeltola, K.
dc.contributor.authorOria, G. A. De Velasco
dc.contributor.authorBurotto, M.
dc.contributor.authorRodriguez, C. Suarez
dc.contributor.authorGhatalia, P.
dc.date.accessioned2025-05-10T19:48:33Z
dc.date.issued2023
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionCongress of the European-Society-for-Medical-Oncology (ESMO) -- OCT 20-24, 2023 -- Madrid, SPAIN
dc.description.abstract[No abstract available]
dc.description.sponsorshipEuropean Soc Med Oncol
dc.description.sponsorshipMerck Sharp Dohme LLC
dc.description.sponsorshipFunding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
dc.identifier.doi10.1016/j.annonc.2023.10.090
dc.identifier.endpageS1330
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.scopusqualityQ1
dc.identifier.startpageS1329
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2023.10.090
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11747
dc.identifier.volume34
dc.identifier.wosWOS:001087480203576
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleBelzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu